New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
09:56 EDTAERI, STL, PRXL, STBZ, ERIC, PEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aerie Pharmaceuticals (AERI) initiated with a Buy at Canaccord... Alliance Fiber Optic (AFOP) initiated with a Buy at Sidoti... Ericsson (ERIC) initiated with a Hold at Jefferies... PAREXEL (PRXL) initiated with a Hold at KeyBanc... Parsely Energy (PE) initiated with a Sector Perform at RBC Capital... State Bank Financial (STBZ) initiated with a Buy at Wunderlich... Sterling Bancorp (STL) initiated with an Outperform at Raymond James.
News For AERI;ERIC;PRXL;PE;STBZ;STL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
11:32 EDTERICF5 Networks plummets after Q2 outlook trails estimates
Subscribe for More Information
January 20, 2015
08:49 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
SunTrust downgraded PAREXEL based on full valuation. Price target remains $65.
06:09 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
January 15, 2015
13:07 EDTERICNetworking trends seen as boon for Cisco, others
Subscribe for More Information
07:02 EDTERICTrends positive for data networking names, says Bernstein
Subscribe for More Information
06:17 EDTERICVodafone CTO Steve Pusey to retire, Johan Wibergh appointed as successor
Subscribe for More Information
January 14, 2015
05:49 EDTERICApple sues Ericsson over patent royalty rates, Bloomberg says
Apple (AAPL) filed a lawsuit against Ericsson (ERIC) in the U.S. District Court for the Northern District of California, stating that Ericsson's royalty rates are excessive and its patents are not essential to LTE standards, reports Bloomberg. Reference Link
05:28 EDTERICEricsson files complaint against Apple in U.S. District Court
Following Apple's (AAPL) action, Ericsson (ERIC) has filed a complaint in the U.S. District Court for the Eastern District of Texas requesting a ruling on Ericsson's proposed global licensing fees with Apple. During the past two years of negotiations, the companies have not been able to reach an agreement on licensing of Ericsson's patents that enable Apple's mobile devices to connect with the world and power many of their applications. Ericsson filed the suit in order to receive an independent assessment on whether Ericsson's global licensing offer complies with Ericsson's fair, reasonable, and non-discriminatory, or FRAND, commitment. The global license agreement between Ericsson and Apple for mobile technology has expired and Apple has declined to take a new license on offered FRAND terms. Ericsson's Q4 IPR revenue will include payment from Apple under previous agreement. Every Apple smartphone and tablet with cellular capability uses technology from Ericsson. On January 12, Apple filed a lawsuit asking the U.S. District Court for the Northern District of California to find that it does not infringe a small subset of Ericsson's patents.
January 13, 2015
08:34 EDTPRXLPAREXEL book-to-bill suggests growth returning, says UBS
Subscribe for More Information
08:34 EDTPRXLPAREXEL sees December quarter exceeding 1.4 book-to-bill ratio
Subscribe for More Information
January 12, 2015
14:18 EDTAERIAerie accelerated data read-out a positive, says Cantor
Subscribe for More Information
06:31 EDTAERIAerie Pharma accelerates of timeline for reporting results from Rhopressa trial
Aerie Pharmaceuticals announced the acceleration of the expected timeline for reporting efficacy results from the company’s 400-patient Phase 3 registration trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of RhopressaTM compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named “Rocket 3.” Pending the continued advancement of the RhopressaTM Phase 3 program and regulatory approvals, Aerie intends to commercialize RhopressaTM in North American markets and possibly Europe with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.
06:21 EDTPEParsley Energy upgraded to Neutral from Sell at Goldman
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use